Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia
Open Access
Abstract
Mutations in TP53 inhibit p53 protective behaviors including cell cycle arrest, DNA damage repair protein recruitment, and apoptosis. The ubiquity of p53 in genome-stabilizing functions leads to an aberrant tumor microenvironment in TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Profound immunosuppression mediated by myeloid-derived suppressor cells, the upregulation of cytokines and cell-surface receptors on leukemic cells, the suppression of native immune regulator cells, and metabolic aberrations in the bone marrow are features of the TP53-mutated AML/MDS marrow microenvironment. These localized changes in the bone marrow microenvironment (BMME) explain why traditional therapies for MDS/AML, including chemotherapeutics and hypomethylating agents, are not as effective in TP53-mutated myeloid neoplasms and demonstrate the dire need for new treatments in this patient population. The unique pathophysiology of TP53-mutated disease also provides new therapeutic approaches which are being studied, including intracellular targets (MDM2, p53), cell-surface protein biologics (immune checkpoint inhibitors, BiTE therapy, and antibody–drug conjugates), cell therapies (CAR-T, NK-cell), signal transduction pathways (Hedgehog, Wnt, NF-κB, CCRL2, and HIF-1α), and co-opted biologic pathways (cholesterol synthesis and glycolysis). In this review, we will discuss the pathophysiologic anomalies of the tumor microenvironment in TP53-mutant MDS/AML, the hypothesized mechanisms of chemoresistance it imparts, and how novel therapies are leveraging diverse therapeutic targets to address this critical area of need.Keywords
This publication has 195 references indexed in Scilit:
- Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4 / DPYSL2A axisFEBS Open Bio, 2025
- The multifunctional proline-rich domain of p53 tumor suppressorBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025
- The role of immune cells settled in the bone marrow on adult hematopoietic stem cellsCellular and Molecular Life Sciences, 2024
- Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapyActa Histochemica, 2024
- Tumor suppressor p53: Biology, signaling pathways, and therapeutic targetingBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Daratumumab in transfusion‐dependent patients with low or intermediate‐1 risk myelodysplastic syndromesAmerican Journal of Hematology, 2021
- P53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versaCellular and Molecular Life Sciences, 2020
- The Bone Marrow Microenvironment for Hematopoietic Stem Cells2017
- Tetramer formation of tumor suppressor protein p53: Structure, function, and applicationsPeptide Science, 2016
- TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics DataHuman Mutation, 2016